Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
Did you know?
What made us buy IEX@193, Tata Power@56, Titan@330, Divis@629, Persistent@700.
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

JB Chemicals & Pharmaceuticals Ltd Stock Analysis

Mid Cap
Evaluated by 2480 users | BSE: 506943 | NSE: JBCHEPHARM |
Pharmaceuticals & Drugs

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
JB Chemicals & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good
Value Creation
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Capital Employed 15.72%15.21%7.58%9.6%10.18%12.28%10.61%7.46%10.89%16.83%22.81%-
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 8076868169571,0611,1651,1991,2551,5011,6411,8922,064
Y-o-Y Gr. Rt.--14.9%18.9%17.2%11%9.8%2.9%4.7%19.6%9.3%15.3%-
Adjusted EPS (Rs.) 14.3315.318.8911.9713.0217.3817.3212.7319.9232.2148.1659.25
Y-o-Y Gr. Rt.-6.8%-41.9%34.7%8.8%33.5%-0.4%-26.5%56.5%61.7%49.5%-
Book Value per Share (Rs.) 84.36112.59119.1123.66119.84144.15163.62173.91185.02187.02233.75254.14
Adjusted Net Profit 12113075.3101110147147106160249372458
Net Op. Cash Flow (Rs. Cr.) 13785180.4-11.7143171178116193272335-
Debt to Cash Flow from Ops 1.230.080.62-7.960.741.020.280.250.130.110.08-
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
JB Chemicals & Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  10 yrs 5 yrs 3 yrs 1 yr
Net Sales 11.9%10.2%14.7%15.3%
Adjusted EPS 13.6%22.6%55.8%49.5%
Book Value per Share 8.510.210.425
Share Price 37% 36.2% 76.8% 63.8%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on Equity (%) 18.2615.567.679.8610.713.1711.257.4910.8816.9922.8924.29
Operating Profit Margin (%) 21.413.814.7716.1818.6219.6418.9815.9319.4622.5829.1927.4
Net Profit Margin (%) 15.0118.99.2210.610.412.6512.258.4810.6415.1719.6722.19
Debt to Equity 0.240.070.050.090.10.140.040.020.020.020.010
Working Capital Days 236230162161162214276290269224191276
Cash Conversion Cycle 1821558797100959698878175226
Loading price chart...
Entity Percentage Holding
Promoters 55.91%
Institutions 23.97%
Non-Institutions 20.12%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Past 10 year's financial track record analysis by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good quality company.

JB Chemicals & Pharmaceuticals Ltd's earnings have grown by 22.6%, whereas share price has appreciated 36.2% CAGR over the past five years, indicating the company’s share price is likely overvalued. However, for specific investment actions please consult your investment advisor.

JB Chemicals & Pharmaceuticals Ltd share price has appreciated 37% annually (CAGR) over the past ten years.

Past 10 years financial track record analysis and assessment of future prospects by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good long term investment. However, you need to ensure you buy at a right price to earn good returns.

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.

Milestones & awards

1996-97

  • Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee

1999

  • J. B. Chemical & Pharmaceuticals Ltd. is honoured with the IDMA Quality Excellence Award: ‘Certificate of Merit’ for distinction in quality manufacturing at its manufacturing unit in Panoli.

2000

  • Company awarded a Golden Status certificate by the Govt. of India.

2001

  • J.B. Chemical & Pharmaceuticals Ltd. receives CHEMEXCIL’s ‘First Award’ for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category. Received South Africa MCA approval for its tablets facility at Panoli.

2003

  • First ANDA filing with USFDA for Ciprofloxacin.
  • First company to market Rantac CD.
  • Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.

2004

  • Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
  • Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
  • UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.

2005

  • TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
  • JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
  • JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.

2006

  • The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.

2007

  • JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’

2008

  • Made a strategic investment in a company in South Africa called Biotech Laboratories.

2011

  • Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.

2016

  •  Resignation of a director - Dr. Niranjan Maniar due to health problem.

2017

  • Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
  • Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.

2018

  • US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension).

2020

  • This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg.
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback